Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:09 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study to Evaluate Esmolol (Brevibloc) to Manage Cardiac Function in Patients With Subarachnoid Hemorrhage
NCT01232400 · University of Michigan · NA · withdrawn · last registry update 2015-01-08 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Funding withdrawn. Design not feasible.” | – | Registry record, University of Michigan |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ADRB1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2015-12-01Phase 3 first posted: Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd., Levobetaxolol eye drops + Betaxolol eye drops (NCT02617459)
- 2015-07-30Phase 3 first posted: Actavis Inc., Test-Brinzolamide 1% Ophthalmic suspension + Reference-Brinzolamide 1% Ophthalmic suspension (NCT02512042)
- 2015-01-05Results posted on the registry: Stanford University, a drug against ADRB1 (NCT00212134)
- 2014-10-29Phase 3 first posted: KK Women's and Children's Hospital, phenylephrine + ephedrine (NCT02277730)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision